Search research articles
Contact Us
Filters
Showing results (41-50 of 56) with videos related to
Page
of 6
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
April 29, 2015
Fusion dual-tracer SPECT-based hepatic dosimetry predicts outcome after radioembolization for a wide range of tumour cell types
Marnix G E H Lam, Arjun Banerjee, Michael L Goris, et al.
Clinical Nuclear Medicine
|
August 21, 2014
Detection of osseous metastasis by 18F-NaF/18F-FDG PET/CT versus CT alone
Srinath C Sampath, Srihari C Sampath, Camila Mosci, et al.
Radiology
|
April 20, 2011
Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels
Erik S Mittra, Michael L Goris, Andrei H Iagaru, et al.
EJNMMI Research
|
August 29, 2020
Initial evaluation of (4S)-4-(3-[<sup>18</sup>F]fluoropropyl)-L-glutamate (FSPG) PET/CT imaging in patients with head and neck cancer, colorectal cancer, or non-Hodgkin lymphoma
Sonya Y Park, Camila Mosci, Meena Kumar, et al.
British Journal of Pharmacology
|
January 11, 2007
Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema?
S Mittra, G Sangle, R Tandon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 3, 2017
Biodistribution and Radiation Dosimetry of <sup>18</sup>F-FTC-146 in Humans
Trine Hjørnevik, Peter W Cipriano, Bin Shen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 4, 2025
Phase 1 Study of [<sup>177</sup>Lu]Lu-NeoB in Patients with Advanced Solid Tumors Overexpressing Gastrin-Releasing Peptide Receptor: Preliminary Safety and Dosimetry Results
Erik S Mittra, Lilja B Solnes, Astrid A M van der Veldt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2012
Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for imaging xC- transporter using positron emission tomography in patients with non-small cell lung or breast cancer
Sora Baek, Chang-Min Choi, Sei Hyun Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 23, 2020
Clinical Evaluation of (4S)-4-(3-[<sup>18</sup>F]Fluoropropyl)-L-glutamate (<sup>18</sup>F-FSPG) for PET/CT Imaging in Patients with Newly Diagnosed and Recurrent Prostate Cancer
Sonya Youngju Park, Sae Jung Na, Meena Kumar, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 13, 2025
Dosimetry of [<sup>177</sup>Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial
Lisa Bodei, Marta Cremonesi, Mahila Ferrari, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 56) with videos related to
Sort By:
Page
of 6
European Journal of Nuclear Medicine and Molecular Imaging
|
April 29, 2015
Fusion dual-tracer SPECT-based hepatic dosimetry predicts outcome after radioembolization for a wide range of tumour cell types
Marnix G E H Lam, Arjun Banerjee, Michael L Goris, et al.
Clinical Nuclear Medicine
|
August 21, 2014
Detection of osseous metastasis by 18F-NaF/18F-FDG PET/CT versus CT alone
Srinath C Sampath, Srihari C Sampath, Camila Mosci, et al.
Radiology
|
April 20, 2011
Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels
Erik S Mittra, Michael L Goris, Andrei H Iagaru, et al.
EJNMMI Research
|
August 29, 2020
Initial evaluation of (4S)-4-(3-[<sup>18</sup>F]fluoropropyl)-L-glutamate (FSPG) PET/CT imaging in patients with head and neck cancer, colorectal cancer, or non-Hodgkin lymphoma
Sonya Y Park, Camila Mosci, Meena Kumar, et al.
British Journal of Pharmacology
|
January 11, 2007
Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema?
S Mittra, G Sangle, R Tandon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 3, 2017
Biodistribution and Radiation Dosimetry of <sup>18</sup>F-FTC-146 in Humans
Trine Hjørnevik, Peter W Cipriano, Bin Shen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 4, 2025
Phase 1 Study of [<sup>177</sup>Lu]Lu-NeoB in Patients with Advanced Solid Tumors Overexpressing Gastrin-Releasing Peptide Receptor: Preliminary Safety and Dosimetry Results
Erik S Mittra, Lilja B Solnes, Astrid A M van der Veldt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2012
Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for imaging xC- transporter using positron emission tomography in patients with non-small cell lung or breast cancer
Sora Baek, Chang-Min Choi, Sei Hyun Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 23, 2020
Clinical Evaluation of (4S)-4-(3-[<sup>18</sup>F]Fluoropropyl)-L-glutamate (<sup>18</sup>F-FSPG) for PET/CT Imaging in Patients with Newly Diagnosed and Recurrent Prostate Cancer
Sonya Youngju Park, Sae Jung Na, Meena Kumar, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 13, 2025
Dosimetry of [<sup>177</sup>Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial
Lisa Bodei, Marta Cremonesi, Mahila Ferrari, et al.
Page
of 6